{"DataElement":{"publicId":"6680236","version":"1","preferredName":"Pancreatic Neuroendocrine Tumor AJCC Edition 8 Group Stage","preferredDefinition":"Stage group based on the combination of T, N, and M categories for pancreatic neuroendocrine tumor using AJCC Ed. 8 criteria.","longName":"PNET_AJC8_DZ_STG","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6679984","version":"1","preferredName":"Pancreatic Neuroendocrine Tumor Stage Grouping","preferredDefinition":"A low or intermediate grade well differentiated tumor with neuroendocrine differentiation that arises from the pancreas.  According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","longName":"5528371v1.0:2230143v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"5528371","version":"1","preferredName":"Pancreatic Neuroendocrine Tumor","preferredDefinition":"A low or intermediate grade well differentiated tumor with neuroendocrine differentiation that arises from the pancreas","longName":"C27720","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Neuroendocrine Tumor","conceptCode":"C27720","definition":"A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the pancreas.  According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F4F7E4E-56D6-7FA1-E053-F662850AC326","latestVersionIndicator":"Yes","beginDate":"2016-10-20","endDate":null,"createdBy":"UMLLOADER_EDRN","dateCreated":"2016-10-20","modifiedBy":"ONEDATA","dateModified":"2016-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"849C7FC6-9F55-2705-E053-F662850AB486","latestVersionIndicator":"Yes","beginDate":"2019-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-21","modifiedBy":"TAYLORT","dateModified":"2019-05-03","changeDescription":"5-3-19 released; tmt. 3/21/19 curated for AJCC ed. 8 content; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6680209","version":"1","preferredName":"Pancreatic Neuroendocrine Tumor American Joint Committee on Cancer Edition 8 Group Stage","preferredDefinition":"A term that refers to the staging of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This staging system applies to well-differentiated neuroendocrine tumors arising in the pancreas. Carcinomas of the pancreas, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas are not staged using this staging system. (from AJCC 8th Ed.)_An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6680209v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IV","valueDescription":"Stage IV Pancreatic Neuroendocrine Tumor AJCC v8","ValueMeaning":{"publicId":"6680216","version":"1","preferredName":"Stage IV Pancreatic Neuroendocrine Tumor AJCC v8","longName":"6680216","preferredDefinition":"Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IV Pancreatic Neuroendocrine Tumor AJCC v8","conceptCode":"C135564","definition":"Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"849D9A8B-017A-5964-E053-F662850A15ED","latestVersionIndicator":"Yes","beginDate":"2019-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-21","modifiedBy":"ONEDATA","dateModified":"2019-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"849D9A8B-0193-5964-E053-F662850A15ED","beginDate":"2019-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-21","modifiedBy":"ONEDATA","dateModified":"2019-03-21","deletedIndicator":"No"},{"value":"III","valueDescription":"Stage III Pancreatic Neuroendocrine Tumor AJCC v8","ValueMeaning":{"publicId":"6680218","version":"1","preferredName":"Stage III Pancreatic Neuroendocrine Tumor AJCC v8","longName":"6680218","preferredDefinition":"Stage III includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery). N0: No regional lymph node involvement. N1: Regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage III Pancreatic Neuroendocrine Tumor AJCC v8","conceptCode":"C135563","definition":"Stage III includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery). N0: No regional lymph node involvement. N1: Regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"849D9A8B-01A0-5964-E053-F662850A15ED","latestVersionIndicator":"Yes","beginDate":"2019-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-21","modifiedBy":"ONEDATA","dateModified":"2019-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"849D9A8B-01B9-5964-E053-F662850A15ED","beginDate":"2019-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-21","modifiedBy":"ONEDATA","dateModified":"2019-03-21","deletedIndicator":"No"},{"value":"II","valueDescription":"Stage II Pancreatic Neuroendocrine Tumor AJCC v8","ValueMeaning":{"publicId":"6680220","version":"1","preferredName":"Stage II Pancreatic Neuroendocrine Tumor AJCC v8","longName":"6680220","preferredDefinition":"Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor limited to the pancreas and measuring 2-4 cm. T3: Tumor limited to the pancreas and measuring more than 4 cm; or tumor invading the duodenum or bile duct. N0: No regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Pancreatic Neuroendocrine Tumor AJCC v8","conceptCode":"C135562","definition":"Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor limited to the pancreas and measuring 2-4 cm. T3: Tumor limited to the pancreas and measuring more than 4 cm; or tumor invading the duodenum or bile duct. N0: No regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"849D9A8B-01C6-5964-E053-F662850A15ED","latestVersionIndicator":"Yes","beginDate":"2019-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-21","modifiedBy":"ONEDATA","dateModified":"2019-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"849D9A8B-01DF-5964-E053-F662850A15ED","beginDate":"2019-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-21","modifiedBy":"ONEDATA","dateModified":"2019-03-21","deletedIndicator":"No"},{"value":"I","valueDescription":"Stage I Pancreatic Neuroendocrine Tumor AJCC v8","ValueMeaning":{"publicId":"6680222","version":"1","preferredName":"Stage I Pancreatic Neuroendocrine Tumor AJCC v8","longName":"6680222","preferredDefinition":"Stage I includes: T1, N0, M0. T1: Tumor limited to the pancreas and measuring less than 2 cm. N0: No regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Pancreatic Neuroendocrine Tumor AJCC v8","conceptCode":"C135561","definition":"Stage I includes: T1, N0, M0. T1: Tumor limited to the pancreas and measuring less than 2 cm. N0: No regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"849D9A8B-01EC-5964-E053-F662850A15ED","latestVersionIndicator":"Yes","beginDate":"2019-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-21","modifiedBy":"ONEDATA","dateModified":"2019-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"849D9A8B-0205-5964-E053-F662850A15ED","beginDate":"2019-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-21","modifiedBy":"ONEDATA","dateModified":"2019-03-21","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6680208","version":"1","preferredName":"Pancreatic Neuroendocrine Tumor by AJCC v8 Stage Stage Grouping Stage","preferredDefinition":"A term that refers to the staging of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This staging system applies to well-differentiated neuroendocrine tumors arising in the pancreas. Carcinomas of the pancreas, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas are not staged using this staging system. (from AJCC 8th Ed.):An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C135560:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Neuroendocrine Tumor by AJCC v8 Stage","conceptCode":"C135560","definition":"A term that refers to the staging of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This staging system applies to well-differentiated neuroendocrine tumors arising in the pancreas. Carcinomas of the pancreas, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas are not staged using this staging system. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"849E04CA-9E17-7429-E053-F662850A80E8","latestVersionIndicator":"Yes","beginDate":"2019-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-21","modifiedBy":"ONEDATA","dateModified":"2019-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"849E04CA-9E28-7429-E053-F662850A80E8","latestVersionIndicator":"Yes","beginDate":"2019-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-21","modifiedBy":"TAYLORT","dateModified":"2019-05-03","changeDescription":"5-3-19 released; tmt. 3/21/19 curated for standardization; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506114","version":"1","longName":"Pancreas","context":"MCL","ClassificationSchemeItems":[{"publicId":"7781144","version":"1","longName":"Pancreas PCA Pilot","context":"MCL"},{"publicId":"5854655","version":"1","longName":"Pancreas Core","context":"MCL"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"10000091","version":"1","longName":"Pancreatic","context":"NCI Standards"}]},{"publicId":"6437797","version":"1","longName":"Pre-Cancer Atlas Pilot","context":"MCL","ClassificationSchemeItems":[{"publicId":"7001793","version":"1","longName":"Pancreas PCA Pilot","context":"MCL"}]}],"AlternateNames":[{"name":"neuroendocrine_group_stage","type":"MCL Alt Name","context":"NCI Standards"},{"name":"MCL","type":"USED_BY","context":"MCL"}],"ReferenceDocuments":[{"name":"Disease stage","type":"Preferred Question Text","description":"Disease stage","url":null,"context":"NCI Standards"},{"name":"MCL-PCA-1","type":"Alternate Question Text","description":"Neuroendocrine Group Stage","url":null,"context":"MCL"},{"name":"MCL-Template Name","type":"Data Collection Template","description":"pancreas_v0-1_template-1.xlsx","url":"https://mcl.nci.nih.gov/resources/standards/mcl-cdes","context":"MCL"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"849C2790-9A79-5921-E053-F662850AF1D7","latestVersionIndicator":"Yes","beginDate":"2019-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-21","modifiedBy":"COLBERTM","dateModified":"2021-09-16","changeDescription":"5-3-19 released; tmt. 3/21/19 curated for standardization; tmt.   8/17/21 mr Added Alt Name and Ref Doc to match MCL DD.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}